Prior to the 2020 Covid-19 pandemic, Glia was in the midst of a calibration trial for our 3D Printed pulse oximeter, which was originally designed by a Slovenian open source company, Institute IRNAS. From 2018-2019, Glia partnered with London Health Sciences Center's Intensive Care Unit to execute the first half of our clinical trial: Calibration & Validation of a Low-Cost Pulse Oximeter.
Unfortunately, the trial was paused because of Covid-19 case surges reducing clinical availability. We are hopeful to regain ICU access in 2023 and restart the study.
When the calibration trial is complete Glia expects to present a fully operational pulse oximeter equal to brand-name counterparts at a fraction of the cost, creating greater accessibility in low-resource settings for this important diagnostic tool. Market research on current pulse oximeters, especially OTC (over-the-counter) brands sold directly to patients, has clearly shown that inaccurate blood oxygenation readings on melanated skin has led to clinical misdiagnosis and possible patient mortality. This disturbing racial bias was a recent catalyst for the 11/1/2022 FDA Advisory Meeting on pulse oximeter accuracy, which has historically been challenged by proprietary dataset algorithms. Glia plans to address this global equity issue by publicly releasing all its research datasets- vital information which will allow any pulse oximeter manufacturer to create equal care for all.
Glia is currently seeking fundraising opportunities to support the next stage of this project. To learn more please visit The Glia Pulse Oximeter project page.
Help support Glia's work, donate to the Glia Project here!
Don't forget to join our mailing list by entering your email address below and stay up to date on our projects, receive information on new devices, projects, releases, and of course to ensure you never miss a release of our newsletter, The Open Source.